New Preclinical Data Shows Samaritan's Cardiovascular Drug Reduces Cholesterol; Cardiovascular Disease is a $15B Market Worldwi
March 28 2006 - 8:27AM
Business Wire
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative
drugs, announced today, it has new preclinical data gathered in a
series of animal studies that shows its Cardiovascular drug SP-1000
reduces blood cholesterol. Lowering cholesterol is a key component
in the prevention and management of heart disease. Earlier
preclinical "in vitro" studies gave Samaritan reason to believe its
proprietary peptide SP-1000 cleans the blood of excessive
cholesterol and corrects high cholesterol conditions in people
affected by the disease. Advancing to animal preclinical studies,
SP-1000 data indicated that it removes cholesterol from the LDL
"bad" cholesterol-apolipoprotein complex and it reduced blood
cholesterol levels in two different types of hypercholesterolemic
"animal models." These models included genetically engineered and
diet-induced hypercholesterolemic, animals. This new preclinical
data is being prepared to submit to a peer-reviewed journal. Dr.
Greeson, CEO of Samaritan stated, "The novelty of SP-1000 as a new
cholesterol therapy lies in its 'mechanism of action,' that is
SP-1000 eliminates excessive cholesterol directly from the blood;
in contrast, to all known current cholesterol therapies where the
mechanism of action entails the enzymes responsible for cholesterol
synthesis in the liver. In addition, our drug comes at a time when
quite a few of the cholesterol lowering statins are about to come
off patent. We believe this is a drug that major pharmaceuticals
will find compelling, as well as the patients who have extreme
difficulty managing their cholesterol levels." Samaritan
Pharmaceuticals: "We LIV....to Save Lives." Samaritan is a
small-cap Biotech, driven to discover, develop, and commercialize,
innovative therapeutics for AIDS, Alzheimer's, cancer and heart
disease. Look at www.samaritanpharma.com. Please register on
Website so we can notify you of upcoming conference calls, news and
events. Disclaimer The company disclaims any information that is
created by an outside party and endorses only information that is
communicated by its press releases, filings and Website. This news
release contains forward-looking statements that reflect
management's current beliefs about the potential for its drug
candidates, science and technology. However, as with any
biopharmaceutical under development, there are significant risks
and uncertainties in the process of development and regulatory
review. There are no guarantees that products will prove to be
commercially successful. For additional information about the
factors that affect the company's business, please read the
company's latest Form 10-K filed April 15, 2005. The company
undertakes no duty to update forward-looking statements.
Emles at Home ETF (AMEX:LIV)
Historical Stock Chart
From Dec 2024 to Jan 2025
Emles at Home ETF (AMEX:LIV)
Historical Stock Chart
From Jan 2024 to Jan 2025
Real-Time news about Emles at Home ETF (American Stock Exchange): 0 recent articles
More Samaritan Pharmaceuticals, Inc. News Articles